Sign In

HCV 2017 Treatment Symposium


  • Monday, October 23, 4:45-6:15 pm

Program Chairs 

  • Andrew J. Muir, MD, FAASLD
  • Donald M. Jensen, MD, FAASLD

Continuing Education Information

  • CME – 1.5 AMA PRA Category 1 Credits™ 

Learning Objectives

Upon completion of this activity, participants will be able to:

  • Apply the current AASLD-IDSA treatment guidelines to making decisions regarding the optimal therapy for naïve patients and those exposed to DAA’s.
  • Provide the best HCV treatment strategies in the era of pangenotypic therapies.
  • Identify the models of care for HCV infection and identify best practices in disease eradication.

Session Description/Needs Statement

This program will include discussions of recently approved regimens and challenging patient populations. The emphasis in these lectures will be on clinical knowledge and application to individual patient management decisions, the AASLD-IDSA Guidance Panel treatment recommendations and global perspectives on disease eradication strategies.

Program Agenda

  • 4:45-4:50 pm
  • 4:50-5:05 pm
    From the AASLD-IDSA Guidance Committee:
    How We Make Our Recommendations, What Important Gaps Remain in the Care of HCV Patients?
    Susanna Naggie, MD
  • 5:05-5:20 pm
    Global Perspectives on HCV Eradication
    Philippa J. Easterbrook, MD, MPH
  • 5:20-5:40 pm
    New HCV Therapies in 2017 and Their Impact on Treatment Strategies
    Paul Y. Kwo, MD, FAASLD
  • 5:40-6 pm
    HCV Patient Populations With Challenging Treatment Decisions
    • Genotype 3
    • Treatment Failures
    • Decompensated Cirrhosis
    • Patients Eligible for Liver Transplantation
    Paul J. Pockros, MD, FAASLD
  • 6-6:15 pm
    Panel Discussion